Treatment for osteoporosis using GRF or a biologically active an

Details Treatment for osteoporosis using GRF or a biologically active an Treatment for osteoporosis using GRF or a biologically active an

1987-07-31

1989-09-26

Phillips, Delbert R.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

424 43, A61K 3736

Patent

active

048700541

ABSTRACT:
A method of treating osteoporosis, especially post-menopausal osteoporosis, by administering on a periodic but regular basis to a patient growth hormone releasing factor, GRF(1-44)-NH.sub.2, or a biologically active analog thereof, and continuing the administration until bone mass increases and the patient's calcium balance becomes positive and indicates a mineral accumulation in the skeleton.

REFERENCES:
patent: 4153689 (1979-05-01), Hirai
patent: 4476116 (1984-10-01), Anik
patent: 4518586 (1985-05-01), Rivier
patent: 4617149 (1986-10-01), DiMarchi
patent: 4710382 (1987-12-01), Recker
Vale, Endocrinology, 112, No. 4, 1553 (1983).
Lance, Biochemical and Biophysical Research Communications, 119, No. 1, 265-272 (1984).

Affiliated with

Also associated with

Rating

Treatment for osteoporosis using GRF or a biologically active an does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment for osteoporosis using GRF or a biologically active an, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment for osteoporosis using GRF or a biologically active an will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-187707